Recommendation: Buy
| Entry Date | Symbol | Recommendation | Entry Price (USD) | Target 1 (USD) | Target 2 (USD) | Holding Duration | Position Status | Return(%)* |
|---|---|---|---|---|---|---|---|---|
| 1 May, 26 | FMC | Buy | USD 14.88 | USD 15.63 | USD 16.5 | 9 days | Closed |
10.62%
|
*Return(%) represent the percentage change between the entry price and exit price of the recommendation.
Data Powered by EOD Historical Data (“EODHD”).
FMC Corporation, an agricultural sciences company, develops, markets, and sells crop protection chemicals in Latin America, North America, Europe, the Middle East, Africa, and Asia. The company offers crop protection chemicals, including insecticides, herbicides, and fungicides. It also provides biologicals, crop nutrition, and seed treatment products. It markets its products through its sales organization and alliance partners, independent distributors, and sales representatives. The company was founded in 1883 and is headquartered in Philadelphia, Pennsylvania.
North America Revenue Growth: Q1FY26 USD 198 Mn vs Q1FY25 USD ~187 Mn
Increase in EMEA Revenue: Q1FY26 USD 307 Mn vs Q1FY25 USD ~272 Mn
Net Loss Expansion: Q1FY26 USD (281) Mn vs Q1FY25 USD (16) Mn
Free Cash Flow Decline: Q1FY26 USD (628) Mn vs Q1FY25 USD (596) Mn
FMC faces significant risks from sustained pricing pressure due to generic competition, high leverage levels, volatile input costs driven by tariffs and geopolitical factors, and execution challenges in its portfolio transition and asset divestment strategy
| Entry Price | Support* | Target 1** | Target 2** |
|---|---|---|---|
| 14.88 | 13.3 | 15.63 | 16.5 |
Data Source: REFINITIV, Analysis: StockNextt
*Support can be considered as an indicative stop-loss, and if prices move below that level on closing basis individuals may evaluate exiting the position depending on their risk appetite, previous holdings, and other factors considered. The support and resistance levels may need to be re-evaluated within 4-6 weeks’ time frame depending on the stock price movements from the date of recommendation on the stock.
**Target prices may vary by ±0.5% depending on market volatility.
Revenue Performance Amid Structural Changes: FMC Corporation reported Q1FY26 revenue of USD 759 million, reflecting a 4% YoY decline, primarily impacted by the exclusion of India operations and pricing pressures across core product segments. However, on a like-for-like basis excluding India, revenue grew by 1%, supported by strong performance in EMEA and North America regions. Growth was driven by higher volumes in herbicides and key products such as Cyazypyr®, partially offset by reduced partner sales and competitive pricing dynamics.
Margin Compression and Profitability Pressures: Profitability weakened significantly during the quarter, with adjusted EBITDA declining 40% YoY to USD 72 million and margins contracting by 570 basis points. This decline was largely attributable to mid-single digit price erosion, higher manufacturing costs due to tariffs and raw material inflation, and reduced contributions from diamide partners. Additionally, GAAP net income deteriorated sharply to a loss of USD 281 million compared to a marginal loss in the prior year, reflecting broader operational pressures.
Strategic Portfolio Realignment and Cost Optimization: The company continues to focus on improving competitiveness of its core portfolio by shifting production to lower-cost regions and restructuring operations, particularly in Asia. These initiatives aim to mitigate cost pressures arising from generic competition and declining pricing in legacy products. FMC is also progressing with the planned divestiture of its India commercial business, which is expected to streamline operations and support balance sheet strengthening.
Growth in New Active Ingredients: A key positive driver remains the strong performance of FMC’s growth portfolio, particularly new active ingredients, whose sales doubled YoY in Q1FY26. Increasing demand for innovative crop protection solutions and new product registrations, including Isoflex approvals in Europe, are expected to drive long-term growth. The company expects these products to contribute meaningfully to volume growth and revenue expansion over the coming years.
Cash Flow and Leverage Dynamics: FMC reported negative free cash flow of USD 628 million in Q1FY26, reflecting weaker operating cash flows due to lower EBITDA and continued restructuring investments. Net debt increased to approximately USD 4.1 billion, with leverage remaining elevated at over 5x EBITDA. The company is actively targeting USD 1 billion in debt reduction through asset sales, licensing agreements, and operational improvements, indicating a strong focus on deleveraging.
Outlook Reflects Continued Near-Term Pressure: Management maintained its FY2026 guidance, expecting revenue in the range of USD 3.6–3.8 billion, representing a ~5% YoY decline, and adjusted EBITDA between USD 670–730 million. The outlook reflects continued pricing pressure, reduced partner sales, and the impact of India divestment, partially offset by volume growth and cost optimization. The company anticipates improved performance in H2FY26, supported by new product momentum and stronger order visibility.
Strategic Review and Long-Term Positioning: FMC is simultaneously evaluating strategic alternatives, including potential asset sales or broader corporate restructuring, to unlock shareholder value. The company remains focused on navigating the post-patent transition of key products like Rynaxypyr® through pricing adjustments and product differentiation strategies. While near-term headwinds persist, management expects operational improvements and growth initiatives to drive recovery from FY2027 onwards.
Considering recent key business, financial updates, current trading levels, and key business risks, a ‘Buy’ recommendation has been given to FMC Corporation (NYSE: FMC) at the current market price of USD 14.88, as on 01 May,2026 at 8:27 am PDT
Data Powered by EOD Historical Data (“EODHD”).
Sector: Basic Materials Industry: Agricultural Inputs
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| FMC FMC Corporation |
-0.02 0.18% | 11.19 | - | 10.27 | 0.57 | 1.05 | 1.67 | 35.08 |
| CTVA Corteva Inc |
-0.52 0.60% | 86.78 | 45.91 | 22.22 | 3.11 | 2.23 | 2.99 | 16.92 |
| NTR Nutrien Ltd |
-0.62 0.92% | 66.66 | 54.62 | 15.27 | 1.14 | 1.17 | 1.64 | 10.45 |
| CF CF Industries Holdings Inc |
2.21 1.82% | 123.63 | 12.92 | 13.97 | 2.63 | 3.85 | 2.86 | 6.18 |
| MOS The Mosaic Company |
0.28 1.27% | 22.41 | 9.17 | 11.07 | 0.78 | 0.98 | 1.00 | 5.38 |
Data Powered by EOD Historical Data (“EODHD”).
Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.
Related Risks: This report may be looked at from high-risk perspective and recommendations are provided are for a short duration. Recommendations provided in this report are solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc.
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels as on May 1, 2026. The reference data in this report has been partly sourced from REFINITIV.
Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned has been achieved and is subject to the factors discussed above.
Note 4: StockNextt reports are prepared based on the stock prices captured either from REFINITIV or Trading View. Typically, REFINITIV or Trading View may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.
Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Target: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Target 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Target 2 may act as the crucial resistance level for the stock.
Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.
Disclaimer :
This report has been issued by StockNextt which has an Ontario Business Identification Number 1000958347 and British Columbia registration Number FM1051529 is a trade name under Kalkine Canada Advisory Services Inc. having Business Number 761925130BC0001. Kalkine Canada Advisory Services Inc. and StockNextt are collectively referred to as “StockNextt”, “we”, “us”, and “our”. The website https://stocknextt.com and associated pages are published by StockNextt. The information in this report and on the StockNextt website has been prepared from a wide variety of sources, which StockNextt, to the best of its knowledge and belief, considers accurate. StcokNextt has made every effort to ensure the reliability of information contained in its reports, newsletters, and websites. All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations for investing in securities and other financial products. StockNextt does not offer financial advice based upon your personal financial situation or goals, and we shall not be held liable for any investment or trading losses you may incur by using the opinions expressed in our reports, publications, market updates, news alerts and corporate profiles. StockNextt does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. StockNextt’s general advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested. Please also read our Terms and conditions for further information. Employees and/or associates of StockNextt and its related entities may hold an interest in the securities or other financial products covered in this report or on the StockNextt website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Copyright © 2026 Krish Capital Pty Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.
Australia